Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Kozuch on the Evaluation of ctDNA in the CIRCULATE-US Trial in Resected CRC

January 10th 2023

Peter Kozuch, MD, discusses the phase 2/3 CIRCULATE-US trial evaluating chemotherapy decisions for patients with resected colorectal cancer based on circulating tumor DNA status.

At-Home Screening Test Demonstrates Sensitivity, Specificity in Detecting CRC

January 10th 2023

Geneoscopy’s at-home, stool-based diagnostic screening test to detect colorectal cancer and advanced adenomas in average-risk individuals displayed high sensitivity and specificity, meeting the primary objectives of the phase 3 CRC-PREVENT trial.

Oxaliplatin Treatment Duration Potentially Linked With Incidence of Severe Neuropathy in Stage III Colon Cancer

January 9th 2023

Patients with stage III colon cancer who receive longer courses of adjuvant oxaliplatin, exercise for less than 9 hours per week, have diabetes, or have a higher body mass index could experience higher rates of severe oxaliplatin-induced peripheral neuropathy.

FDA Grants Breakthrough Therapy Designation to Adagrasib Plus Cetuximab for KRAS G12C–Mutated Advanced CRC

December 22nd 2022

The FDA has granted a breakthrough therapy designation to adagrasib plus cetuximab in patients with KRAS G12C–mutated, advanced colorectal cancer whose cancer has progressed following prior treatment with chemotherapy and an anti-VEGF therapy.

Neoadjuvant Treatment Sequencing Warrants Personalized Considerations in Rectal Cancer

December 20th 2022

Melissa A. Lumish, MD, discusses emerging treatment strategies that could lead to more individualized treatment plans for patients with rectal cancer.

COM701 Plus Nivolumab Confers Modest Efficacy in Metastatic MSS-CRC

December 19th 2022

COM701 plus nivolumab demonstrated modest antitumor activity but a favorable safety profile in patients with metastatic microsatellite stable colorectal cancer.

FDA Approves Updated Labeling for Capecitabine Tablets

December 15th 2022

The FDA has approved updated labeling for capecitabine tablets (Xeloda) under an initiative aimed to ensure labeling information is clinically meaningful and scientifically up to date.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Dr. Klempner on the Investigation of Adagrasib in KRAS G12C–Mutated mCRC

November 30th 2022

Sam Klempner, MD, discusses the investigation of adagrasib in KRAS G12C–mutated metastatic colorectal cancer.

NT-I7/Pembrolizumab Combo Shows Clinical Efficacy in MSS CRC and Pancreatic Cancer Without Liver Metastasis

November 30th 2022

The combination of NT-I7 and pembrolizumab showed significant clinical activity in checkpoint inhibitor–naïve, relapsed/refractory microsatellite stable colorectal cancer and pancreatic cancer without liver metastasis.

Regorafenib Plus Ipilimumab and Nivolumab Shows Intriguing Activity in MSS mCRC

November 8th 2022

Regorafenib plus ipilimumab and nivolumab led to encouraging survival and responses in approximately half of patients with microsatellite stable, non–liver metastatic colorectal cancer who progressed on prior chemotherapy.

Investigators Highlight Top Advances at ESMO 2022

November 7th 2022

Data presented at the ESMO Congress 2022 highlighted advances across treatment modalities, including landmark data for trials in melanoma, breast cancer, and lung cancer, as well as early data that made headlines in a subgroup of patients with colon cancer.

Dr. Barzi on the Need for More Sensitive MRD Testing in CRC

November 3rd 2022

Afsaneh Barzi, MD, PhD, discusses the need for more sensitive minimal residual disease testing in colorectal cancer.

Dr. Klempner on the Unique Trial Design of KRYSTAL-1 in CRC

November 2nd 2022

Sam Klempner, MD, discusses the design and eligibility criteria of the ongoing phase 1/2 KRYSTAL-1 trial in colorectal cancer.

CRC Tumor Sidedness Plays an Increasing Role in Clinical Practice

October 31st 2022

Prognosis, treatment outcomes, and molecular characteristics have become associated with sidedness in colorectal cancers making the distinction an essential characteristic for consideration in decison-making.

Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC

October 29th 2022

Benjamin Adam Weinberg, MD, discussed the expanding role of circulating tumor DNA in CRC and the various testing methods, the utilization of liquid biopsies, and the need for up-front genetic testing to identify molecular alterations.

MOUNTAINEER Data Confirm Clinical Benefit of Tucatinib Plus Trastuzumab in HER2+ mCRC

October 28th 2022

Additional analyses of the phase 2 MOUNTAINEER trial further support the early administration of tucatinib in combination with trastuzumab as an optimal treatment strategy for patients with previously treated HER2-positive metastatic colorectal cancer.

Dr. Cohen on the Use of ctDNA for Chemotherapy Decisions in CRC

October 26th 2022

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

ctDNA Helps Predict Recurrence in Real-World Analysis of Patients With Resected CRC

October 21st 2022

Stacey A. Cohen, MD, discusses the results of real-world analysis of patients with resected stage I-III colorectal cancer, how circulating tumor DNA status correlated with recurrence rates, and how these real-world data compared with previous observational studies.

177Lu-FAP-2286 Displays Preliminary Antitumor Activity in Advanced or Metastatic Solid Tumors

October 18th 2022

Lutetium-177-FAP-2286 produced preliminary evidence of antitumor activity with a manageable safety profile in patients with advanced or metastatic solid tumors, according to data from the phase 1/2 LuMIERE trial.